Ken Griffin Vericel Corp Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$42.25 - $53.56 $207,025 - $262,444	-4,900 Reduced 12.34%	34,800 $1.47 Million
Q2 2024 Aug 14, 2024	BUY	$41.71 - $52.9 $1.03 Million - $1.31 Million	24,800 Added 166.44%	39,700 $1.82 Million
Q1 2024 May 15, 2024	BUY	$32.52 - $52.33 $318,696 - $512,834	9,800 Added 192.16%	14,900 $775,000
Q4 2023 Feb 14, 2024	BUY	$30.85 - $37.09 $18,510 - $22,254	600 Added 13.33%	5,100 $181,000
Q3 2023 Nov 14, 2023	SELL	$31.69 - $39.25 $41,197 - $51,025	-1,300 Reduced 22.41%	4,500 $150,000
Q2 2023 Aug 14, 2023	SELL	$29.0 - $38.37 $693,100 - $917,042	-23,900 Reduced 80.47%	5,800 $217,000
Q1 2023 May 15, 2023	BUY	$23.85 - $31.34 $64,395 - $84,618	2,700 Added 10.0%	29,700 $870,000
Q4 2022 Feb 14, 2023	BUY	$17.65 - $27.37 $476,549 - $738,990	27,000 New	27,000 $711,000

276

48.8M

91.8K

23.2K

Ticker VCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,178,000
Market Cap $2.48B
Description
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.